<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="94002">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01797055</url>
  </required_header>
  <id_info>
    <org_study_id>MD2009.04</org_study_id>
    <nct_id>NCT01797055</nct_id>
  </id_info>
  <brief_title>Apotransferrin in Atransferrinemia</brief_title>
  <official_title>Dose Escalating Study to Evaluate Pharmacokinetics, Efficacy and Safety of Apotransferrin in Atransferrinemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanquin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanquin</source>
  <oversight_info>
    <authority>Spain: Agencia Espa√±ola de Medicamentos y Productos Sanitarios</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atransferrinemia is a very rare disorder, which is caused by a deficiency of the protein
      transferrin. No regular treatment is available for these patients. The objective of this
      study is to investigate the pharmacokinetics, efficacy and safety of Apotransferrin
      replacement therapy in atransferrinemia patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hemoglobulin</measure>
    <time_frame>2 year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>first infusion</time_frame>
    <safety_issue>No</safety_issue>
    <description>serum transferrin levels measured on several time points before and after infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>iron overload in organs</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>transferrin levels</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>adverse drug reactions</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Congenital Atransferrinemia</condition>
  <arm_group>
    <arm_group_label>human apotransferrin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous apotransferrin every 4-8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human apotransferrin</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>human apotransferrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of atransferrinemia, defined as serum levels of transferrin
             below 40 mg/dl

          -  Informed consent

        Exclusion Criteria:

          -  Known with allergic reactions against human plasma or plasma products

          -  Having detectable anti-immunoglobulin A antibodies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C R Diaz de Heredia Rubio, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vall d'Hebron, Spain</affiliation>
  </overall_official>
  <overall_official>
    <last_name>K Moser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>klinikum Aschaffenburg, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Biondi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AO San Gerardo Monza, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilona Kleine Budde, PhD</last_name>
    <email>i.kleinebudde@sanquin.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Paul Strengers, MD</last_name>
    <email>p.strengers@sanquin.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K Moser, MD</last_name>
    </contact>
    <investigator>
      <last_name>K Moser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Biondi, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Biondi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C R Diaz de Heredia Rubio, PhD, MD</last_name>
    </contact>
    <investigator>
      <last_name>C R Diaz de Heredia Rubio, PhD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 31, 2013</lastchanged_date>
  <firstreceived_date>February 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>transferrin</keyword>
  <keyword>anemia</keyword>
  <keyword>iron overload</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metal Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
